Compliance ramifications of proposed $26B opioid deal for pharma industry
By 
Jaclyn Jaeger2021-07-29T17:27:00
Three major drug distributors and drugmaker Johnson & Johnson reached a proposed $26 billion multistate agreement for their alleged roles in fueling the nationwide opioid epidemic. The settlement imparts compliance lessons on the pharmaceutical industry at large.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
News BriefDOJ intervenes in suit alleging Rite Aid helped fuel opioid crisis
The Department of Justice announced its intervention in a lawsuit alleging retail pharmacy chain Rite Aid filled hundreds of thousands of prescriptions for medically unnecessary oxycodone and other opioids in violation of multiple federal laws.
-
ArticleWalmart to pay $3.1B in nationwide opioid settlement
Walmart announced it agreed to a $3.1 billion nationwide settlement designed to resolve all the potential state lawsuits it faces for its alleged role in fueling the opioid epidemic.
-
ArticleOpioid cases against retail pharmacy chains yield compliance lessons
Two cases involving five retail pharmacy chains winding their way through court foretell a long and costly road ahead for all companies across the pharmaceutical supply chain battling litigation for their alleged roles in fueling the opioid epidemic.
More from Regulatory Enforcement
-
ArticleTeledyne fined $1.5M for supplying obsolete parts to Navy
Teledyne will pay more than $1.5 million to settle allegations it supplied electronic parts to the Navy that deviated from specifications, a violation of the False Claims Act (FCA). But its cooperation with prosecutors earned it a credit, according to the U.S. Department of Justice (DOJ).
-
ArticleTungston rod importer pays $54.4M to settle DOJ tariff fraud allegations
An industrial products distributor has agreed to pay $54.4 million to settle allegations, first made by a whistleblower, that it evaded tariffs and violated the federal False Claims Act.
-
ArticleTariff evasion enforcement: The new FCPA
Companies that import goods into the United States will face heightened enforcement scrutiny for attempted acts of customs fraud, including tariff evasion, under the Trump administration. Thus, chief compliance officers and in-house counsel face a new kind of pressure to ensure they are mitigating risk in this area.